Results 71 to 80 of about 30,927 (236)

Ibrutinib and fungus: an invasive concern [PDF]

Blood, 2018
In this issue of Blood, Ghez et al report on 33 patients who developed invasive fungal infections during ibrutinib treatment, the majority of which were invasive aspergillosis, which supports the observation that fungal infections are a potential risk with ibrutinib ...
openaire   +3 more sources

Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options?

European Journal of Haematology, EarlyView.
ABSTRACT Mantle Cell Lymphoma (MCL) is an aggressive B‐cell non‐Hodgkin lymphoma characterized by the hallmark t(11;14)(q13;q32) translocation, resulting in cyclin D1 overexpression. Predominantly affecting elderly males, MCL exhibits marked clinical and biological heterogeneity, ranging from indolent SOX11‐negative variants to highly proliferative ...
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source

Prolonged and tunable residence time using reversible covalent kinase inhibitors. [PDF]

, 2015
Drugs with prolonged on-target residence times often show superior efficacy, yet general strategies for optimizing drug-target residence time are lacking.
Angelina Bisconte, Dane E. Karr, Danny Tam, David Finkle, David G. Loughhead, David M. Goldstein, Erik Verner, J. Hill, J. Michael Bradshaw, Jack Taunton, Jens Oliver Funk, Jesse M. Mcfarl, Jin Shu, Ken A. Brameld, Mary E, Philip A. Nunn, Principia Biopharma, Sergei Romanov, Timothy D. Owens, Tony Ton, Vaishali Patel, Vernon T. Phan, Ville O. Paavilainen, Xiaoyan Li   +23 more
core  

Ibrutinib for Relapsed / Refractory CLL: A UK and Ireland Analysis of Outcomes in 315 patients [PDF]

, 2016
In 2014, ibrutinib was made available for relapsed/refractory chronic lymphocytic leukaemia (CLL) patients. The UK CLL Forum collected data from UK/Ireland patients with a minimum of 1 year follow-up with pre-planned primary endpoints; the number of ...
, UK CLL Forum, Allen, J, Arnold, J, Badat, M, Balotis, C, Bienz, N, Bloor, A, Blundell, J, Bowles, KM, Campbell, G, Cwynarski, K, De Lord, C, Dearden, C, Duncombe, AS, Dyer, MJ, Ewings, M, Fegan, C, Follows, GA, Forconi, F, Fox, CP, Gribbon, J, Hamblin, M, Hodson, A, Hutchinson, C, Jacob, A, Karanth, M, Kennedy, DB, Kirkwood, AA, Knight, H, Kumar, E, Leach, M, Maughan, E, McNichol, F, Milne, AE, Mir, N, Morley, N, Nielson, J, Parry, H, Philpott, N, Pocock, C, Pratt, G, Ringshausen, I, Schuh, A, Scott, F, Tucker, D, Vendenberghe, E, von Barsewisch, B, Wallis, J, Whalley, I, Whiteway, A, William, C   +50 more
core   +3 more sources

Classification of Platelet‐Activating Anti‐Platelet Factor 4 Disorders

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction The prototypic anti‐platelet factor 4 (PF4) disorder—heparin‐induced thrombocytopenia and thrombosis (HITT)—features immunoglobulin G (IgG) class antibodies that activate platelets, monocytes, and neutrophils in a mainly heparin‐dependent fashion via Fcγ receptor‐dependent cellular activation.
Theodore E. Warkentin
wiley   +1 more source

The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib, 5-aminoimidazole-4-carboxamide riboside or venetoclax [PDF]

, 2018
Fluorizoline is a new synthetic molecule that induces apoptosis by selectively targeting prohibitins. In the study herein, the pro-apoptotic effect of fluorizoline was assessed in 34 primary samples from patients with chronic lymphocytic leukemia ...
Albericio Palomera, Fernando, Banda, Esmeralda de la, Cosialls Castel, Ana Mª, Gil i Santano, Joan, González Barca, Eva, González Gironés, Diana M., Iglesias i Serret, Daniel, Lavilla Grífols, Rodolfo, Núñez-Vázquez, Sonia, Pomares, Helena, Pons i Irazazábal, Gabriel, Preciado Gallego, Sara, Saura-Esteller, José   +12 more
core   +1 more source

Mycosis Fungoides, Sézary Syndrome, and Cutaneous B‐Cell Lymphomas: 2025 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, Volume 100, Issue 9, Page 1603-1628, September 2025.
ABSTRACT Disease Overview Primary cutaneous lymphomas are a rare and heterogeneous group of extranodal lymphomas that require the integration of clinical and histopathologic data for classification and treatment. Diagnosis Diagnosis and disease classification is based on histopathologic review and immunohistochemical staining of an appropriate skin ...
Alexandra C. Hristov, Trilokraj Tejasvi, Ryan A. Wilcox   +2 more
wiley   +1 more source

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies [PDF]

, 2012
Ranjana H. Advani, Joseph J. Buggy, Jeff P. Sharman, Sonali M. Smith, Thomas E. Boyd, Barbara Grant, Kathryn S. Kolibaba, Richard R. Furman, Sara Rodríguez, Betty Chang, Juthamas Sukbuntherng, Raquel Izumi, Ahmed Hamdy, Eric Hedrick, Nathan Fowler   +14 more
openalex   +1 more source

British Society for Haematology updated guidelines for the diagnosis and management of tumour lysis syndrome in adults and children with haematological malignancies: A focus on patient safety

British Journal of Haematology, EarlyView.
Y. L. Tracey Chan, Dima El‐Sharkawi, Paras Shah, Dimitrios Chanouzas, David O'Connor, Stephen D. Marks, Gail Jones, on behalf of the BSH Committee   +7 more
wiley   +1 more source

Five years of ibrutinib in CLL [PDF]

Blood, 2018
The study by Ahn et al in this issue of Blood is an important clinical update with a 5-year follow-up on efficacy and toxicity of single-agent ibrutinib, an inhibitor of B-cell receptor (BCR) pathway–associated Bruton tyrosine kinase (BTK), in patients with chronic lymphocytic leukemia (CLL ...
openaire   +3 more sources